WallStreetMyWay
12 years ago
Blackrock High Income (NYSE:HIS) declared a monthly dividend on Monday, February 4th. Stockholders of record on Friday, February 15th will be given a dividend of $0.02 per share on Thursday, February 28th. This represents a $0.18 dividend on an annualized basis and a yield of 7.66%. The ex-dividend date of this dividend is Wednesday, February 13th.
Blackrock High Income (HIS) traded up 0.84% on Monday, hitting $2.40. Blackrock High Income (HIS) has a 52-week low of $2.04 and a 52-week high of $2.52. The stockโs 50-day moving average is currently $2.37. The company has a market cap of $131.4 million and a price-to-earnings ratio of 8.24.
BlackRock High Income Shares (the Trust) is a perpetual closed-end taxable bond fund. The Trust seeks to provide high current income and to a lesser extent capital appreciation!!
Blackrock High Income Announces Monthly Dividend of $0.02 (HIS)
johnsyn
12 years ago
Declaration- 8/1/2012 Ex-Date- 8/13/2012 Record- 8/15/2012 Payable- 8/31/2012
Change From
Fund Ticker Distribution Prior
Distribution
BlackRock Senior High Income Fund, Inc. ARK $0.025000 -
BlackRock Floating Rate Income Trust BGT $0.077500 -
BlackRock Strategic Bond Trust BHD $0.084500 -
BlackRock Core Bond Trust BHK $0.073000 -
BlackRock Defined Opportunity Credit Trust BHL $0.068500 -
The BlackRock High Yield Trust BHY $0.044500 -
The BlackRock Income Trust, Inc. BKT $0.040500 -
BlackRock Limited Duration Income Trust BLW $0.107500 -
BlackRock Income Opportunity Trust, Inc. BNA $0.057000 -
BlackRock Credit Allocation Income Trust III BPP $0.063500 -
BlackRock Credit Allocation Income Trust IV BTZ $0.078500 -
BlackRock Corporate High Yield Fund, Inc. COY $0.051000 -
BlackRock Corporate High Yield Fund III, Inc. CYE $0.052500 -
BlackRock Debt Strategies Fund, Inc. DSU $0.027000 -
BlackRock Diversified Income Strategies Fund, Inc. DVF $0.058500 -
BlackRock Enhanced Government Fund, Inc.* EGF $0.070000 -
BlackRock Floating Rate Income Strategies Fund, Inc. FRA $0.077000 -
BlackRock Floating Rate Income Strategies Fund II, Inc. FRB $0.073000 -
BlackRock High Income Shares HIS $0.015200 -
BlackRock Corporate High Yield Fund VI, Inc. HYT $0.087500 -
BlackRock Corporate High Yield Fund V, Inc. HYV $0.090000 -
BlackRock Credit Allocation Income Trust I, Inc. PSW $0.059500 -
BlackRock Credit Allocation Income Trust II, Inc. PSY $0.061000 -
unevilfavouredness
14 years ago
Cannabis Science Extracts Kill Cancer Cells In Cancer Patients Being Treated Through Its Licensed Distributor Rockbrook
February 22, 2011
DENVER--(BUSINESS WIRE)-- Cannabis Science, Inc. (OTCBB:CBIS.ob - News) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana derivative) products, is pleased to announce that numerous patients are reporting that Cannabis Science extract treatments are killing cancer cells. Cannabis Science, in conjunction with Rockbrook, its Colorado-licensed dispensary, consulted with a variety of cancer patients who were seeking to inform themselves of the current peer reviewed scientific literature, regarding the historical use of cannabis to treat "tumorsโ. Unlike most conventional cancer treatments, cannabis has an outstanding safety profile, and patients in states with medical marijuana laws are able to make an informed decision to legally try various cannabis preparations to determine what is most effective for their particular condition.
Some of these scientifically informed patients have chosen to self-administer Cannabis Science extracts supplied by Rockbrook to treat their own cancers. Cannabis Science is delighted that patients are reporting dramatic improvements in their conditions, including basal cell carcinoma, non-small cell lung cancer accompanied by COPD (chronic obstructive pulmonary disease), ovarian cancer, and glioma.
Please visit www.cannabisscience.com to view the โBreaking Newsโ of the successful results and images of the self-administered cancer treatments.
For example, a patient with basal cell carcinoma used a topical formulation to dramatically and rapidly eliminate her obvious skin cancer. Meanwhile, patients with internal tumors used oral formulations for their treatment. We currently await more complete clinical evaluations of the patientsโ own reports of dramatic health improvements coincident with tumor shrinkage and disappearance.
Dr. Robert J. Melamede, the CEO and President of Cannabis Science Inc., stated, "We will pursue and acquire intra-state generated data to make these cancer medicines available to the public at large as rapidly as possible. To accomplish this goal, we will seek accelerated FDA approval. We are on the verge of a revolution in medicine. Cannabis is now returning to modern medicine for all the right reasons. State generated results give us a unique ability to acquire scientific and clinical data for cannabis-based cancer treatments. As previously announced, we will use our new laboratory facility to house analytical instrumentation, tissue culture, clean rooms and additional necessary equipment. This facility will meet or exceed all federal, state, and local requirements to allow for the necessary for FDA clinical trials.โ
Cannabis Science expects to hold a press conference soon to formally announce its cancer formulation progress and future plans for cancer treatments. Brand names for our new cancer treatment drugs are currently being vetted through the company attorney for future commercial use.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements; This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Cannabis Science Inc.
Dr. Robert J. Melamede
President & CEO
info@cannabisscience.comThis e-mail address is being protected from spambots. You need JavaScript enabled to view it
www.cannabisscience.com
1-888-889-0888
Mark J. Friedman
Investor Relations
info@cannabisscience.comThis e-mail address is being protected from spambots. You need JavaScript enabled to view it
www.cannabisscience.com
1-877-431-CBIS (2247)
unevilfavouredness
14 years ago
"For those about to rock, we salute you!"
I don't get it, this CEF should be one of the hottest symbols on the exchange and talked about on I-HUB. It's under $5.00, trades every day, spits out an 8% divi, and isn't going anywhere because there is a better chance the NY-FED will fail before Blackrock will even flinch. Forget about "deep pockets", these guys have duffle-bags full of gold bullion sewn to their pant-legs. I was at the Ivy Last night chatting it up with some of the good ole boys and one very smart girl at the bar while singing kareokee covers of Kenny Rodger's song; "The Gambler". We all agreed that this is one of the safest bets with the least risk.
I would love to see Janice Shell and her Posse of British Basher's thoughts about HIS. This is about to rock the market. Watch for a rise to $3.00. People are sick of banks. Who needs a 1.73% yielding savings account at a bank with minimum deposit of $10,000.00 when we have Blackrock HIS Closed End Funds yielding 8% with pre-taxed DRIPS available for just over $2.00 a share with a minimum deposit of $500.00 at any on line broker or even a Scottrade located in a strip mall near you?
"Good things come to those that wait, but greater things come to those who when and when not to hesitate"